Pfizer completes acquisition of two GSK meningitis vaccines

In a move to ease antitrust concerns ahead of its multibillion-dollar asset swap with Novartis ($NVS), GlaxoSmithKline ($GSK) announced in June that it would sell two of its mature meningitis jabs to Pfizer ($PFE). The $130 million acquisition of Mencevax and Nimenrix has now closed. Both are marketed outside the U.S. and target the A, C, Y and W strains, but not the B strain. More

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.